The purpose of this investigation was to identify factors that determine the blood level of hepatitis C virus (HCV) RNA. By use of a quantitative polymerase chain reaction assay, the level of HCV RNA was ascertained in stored serum samples from 676 women enrolled in a multicenter prospective investigation who were seropositive for anti-HCV antibodies. HCV RNA levels ranged from undetectable to copies/mL in these women. Among the 6 22.4 ϫ 10 520 women with detectable HCV RNA, levels were higher among those who were 141 years old and those who had human immunodeficiency virus (HIV) infection. After adjusting for age in a multivariate linear regression model, HCV RNA levels were more strongly associated with HIV RNA levels than with CD4 + lymphocyte counts. However, !6% of person-to-person variance was explained by the factors evaluated. Additional research is needed to ascertain what determines the level of HCV RNA in blood.
22.4 ϫ 10 520 women with detectable HCV RNA, levels were higher among those who were 141 years old and those who had human immunodeficiency virus (HIV) infection. After adjusting for age in a multivariate linear regression model, HCV RNA levels were more strongly associated with HIV RNA levels than with CD4 + lymphocyte counts. However, !6% of person-to-person variance was explained by the factors evaluated. Additional research is needed to ascertain what determines the level of HCV RNA in blood.
Hepatitis C virus (HCV) principally replicates in the liver, and HCV RNA can be detected in the blood of chronically infected persons [1, 2] . In most persons, the quantity of HCV RNA peaks in the first weeks of infection and then declines to a relatively stable level that persists indefinitely [1, 3, 4] . Blood levels of HCV RNA may vary by 13 orders of magnitude among untreated persons [5] . The blood level of HCV RNA is increased in persons with human immunodeficiency virus (HIV) infection and also appears to be higher in older persons and those with other forms of immunosuppression [6] [7] [8] [9] . However, in 1 recent study, !10% of the person-to-person variability in HCV RNA levels was explained by these factors [5] . Thus, factors that determine blood HCV RNA levels are poorly understood, especially those among women, who have been underrepresented in prior investigations.
The purpose of our investigation was to assess factors that affect HCV RNA levels in a large multicenter cohort of HCVinfected women with or at risk for HIV infection.
Participants and Methods
Study participants. From April 1993 through February 1995, 1994 women were screened and 1310 (66%) were enrolled in the HIV Epidemiologic Research (HER) Study, as described elsewhere [10] . Women who were 16-55 years old were recruited at 4 sites: Baltimore (The Johns Hopkins School of Hygiene and Public Health), Bronx, NY (Montefiore Medical Center), Providence, RI (Brown University), and Detroit (Wayne State University School of Medicine). Each site aimed to enroll 230 HIV-infected and 115 HIV-uninfected women who were involved in behavior that put them at risk for HIV infection, either drug use (injecting illicit drugs at least once since 1985) or sexual (having had 14 sex partners in the previous 5 years, having had sex with an HIV-infected man or an injection drug user, or having exchanged sex for money or drugs). Women were excluded if they had a history of an AIDSdefining condition. Of 1310 enrolled, 871 were HIV infected.
At each semiannual study visit, participants received a physical examination and a face-to-face interview based on standardized written forms. In addition, blood was collected and centrifuged, and aliquots were either sent for serologic testing or stored at Ϫ70ЊC within 2 h of collection. Serum samples were tested for HIV and HCV and serologic evidence of herpes simplex virus, hepatitis B virus (HBV), and syphilis. Study retention rates were 191%, 88%, and 84% for the second, third, and fourth study visits, respectively. Laboratory testing. Presence of HIV antibody was determined by using an EIA; positive results were confirmed by Western blot. CD4 ϩ T lymphocyte counts were assessed by using flow cytometry. HIV RNA levels were ascertained by using either second-or thirdgeneration Quantiplex branched DNA assays (Chiron). HBV surface antigen (HBsAg) was evaluated by using the Austria II-125 RIA (Abbott Laboratories), and antibody to HBV core (anti-HBc) was examined by using the Corab anti-HBc competitive RIA (Abbott).
The earliest available stored serum samples were used for HCV testing. Serum samples had been centrifuged within 4 h of collection, shipped via overnight carrier for central storage, and frozen the day of receipt at Ϫ70ЊC. Once at the viral testing laboratory, these samples were not thawed until virus load testing was performed. HCV antibodies were assessed by EIA (either EIA 2.0 [Abbott] or ELISA 3.0 [Ortho Diagnostic Systems]); reactive serum samples underwent confirmatory testing by either the MATRIX dot blot immunoassay (Abbott) or the RIBA 3.0 strip immunoblot assay (Chiron). Serum samples reactive by immunoassay and confirmatory tests were considered to be anti-HCV positive.
The quantity of HCV RNA was assessed by polymerase chain reaction in the earliest available, previously unthawed stored serum sample for all women who were positive for anti-HCV antibodies, by using the COBAS MONITOR assay (Roche Molecular Systems). Because 130% of the HCV RNA levels of the first 80 samples tested exceeded the linear range of the assay, all those that exceeded and 9 samples previously in the linear range were retested after another freeze thaw and a 10-fold dilution of serum samples (10 mL into 90 mL of PBS). Among those previously in the linear range, the 9 repeated results were all within 0.5 log, and all those that previously exceeded the linear range had levels within. All remaining specimens were then tested after 10-fold dilution, and !3% of samples with detectable HCV RNA were above the limit of detection. Test results were multiplied by 10 to extrapolate the HCV RNA level.
HCV genotype was assessed by examination of E1 Haming distances between subjects, and prototype sequences were acquired from GenBank, as described elsewhere [11] . In particular the Core/ E1 primers used were as follows: outer, 493S_H77 (493), 5 -GCAA-CAGGGAACCTTCCTGGTTGCTC-3 , and 987R_H77 (987), 5 -CGTAGGGGACCAGTTCATCATCAT-3 ; inner, 5 -502S_H77 (502), 5 -AACCTTCCTGGTTGCTCTTTCTCTAT-3 , and 975R_ H77 (975), 5 -GTTCATCATCATATCCCATGCCAT-3 (nucleotide positions are relative to the 5 base of the Hutchinson 77 genome).
Statistical analysis. The distribution of HCV RNA levels was examined with respect to HIV status, age, race, alcohol ingestion, illicit drug use, HBV infection, and, among HIV-seropositive women, also with respect to CD4 ϩ lymphocyte counts and HIV RNA levels. HCV RNA levels were log 10 transformed, but their distribution remained nonnormal. Thus, nonparametric tests (e.g., the KruskalWallis and Spearman rank correlation tests) were used to infer statistical inferences across multiple levels of explanatory variables. We used linear regression to further characterize variation in the rank order of HCV RNA levels as a function of variables that were associated in univariate analyses. The degree of fit was represented by the adjusted r 2 . Unless otherwise indicated, continuous covariates were categorized into quartiles to maintain consistency with other variates and to demonstrate the magnitude of the differences ob- served. The same levels of association were seen among HIV-seropositive women with HIV RNA levels in the lower 2 quartiles of those with detectable HIV RNA. Thus, HIV RNA levels among women with detectable levels were categorized as less than the median, the median to the upper quartile, and the highest quartile and were compared with those of HIV-seronegative women.
Results
Of the 1310 women enrolled in the HER study, 766 acknowledged prior injection drug use. Of these, 676 women (88.3%) were seropositive for anti-HCV antibodies and had stored specimens available for measurement of HCV RNA levels.
The HCV RNA levels among the 676 women with anti-HCV antibodies ranged from undetectable (!10,000 copies/mL) to copies/mL. Of these, 520 with detectable HCV RNA 6 22.4 ϫ 10 were significantly more likely to be HIV positive ( ) and P p .001 black (
) and were less likely to have chronic HBV infection P ! .05 (HBsAg positive; ) than those with HCV RNA levels P ! .02 !10,000 copies/mL (data not shown).
Among the women with detectable HCV RNA, the quantity increased significantly with age: a median of 6.11 log 10 in women !33 years old and 6.42 log 10 in those 141 years old (table 1) . However, no differences were detected in the HCV RNA levels of black women compared with white women or women of other racial groups, nor was any relationship detected with HCV RNA level and study site, duration since first use of injection drugs, time since last injection, or frequency of alcohol ingestion. In addition, median HCV RNA levels were similar in HBsAg-positive and HBsAg-negative women (6.37 and 6.30 log 10 , respectively). No differences were detected in the HCV level of women with various HCV genotypes.
HCV RNA levels were higher in 386 HIV-seropositive than in 134 HIV-seronegative women. In addition, among HIVseropositive women, HCV RNA levels increased with declining CD4 ϩ lymphocyte counts and increasing HIV RNA levels. The association of HIV RNA level with HCV RNA level was especially evident in women with CD4 ϩ lymphocyte counts 1500 cells/mL (figure 1). A multivariate linear regression model was constructed from factors associated with HCV RNA levels on univariate analyses. The model was limited to women who were HIV seropositive; included age, HIV virus load, and CD4 ϩ lymphocyte count; and used rank of the HCV RNA as the outcome. Age 141 years ( ) and increased HIV RNA levels ( P p .01 P p for the quartile including the median to the 75th percentile .06 and for the highest quartile, compared with HIV-se-P p .002 ropositive women with undetectable HIV RNA) were independently associated with higher levels of HCV RNA. However, !6% of the person-to-person variability in HCV RNA levels was explained by this model (adjusted ).
2 r ! .06
Discussion
In this investigation, higher HCV RNA levels were found in women who were older and were HIV infected, an effect that was more strongly related to HIV RNA level than to CD4 ϩ lymphocyte count. Other investigators also have shown HCV RNA levels to be higher in HIV-infected persons, and some JID 2001; 183 (15 March) have reported that HCV RNA levels increase with declining CD4 ϩ lymphocyte counts [5] [6] [7] [8] [9] . HCV RNA levels also appear to increase with age and with time since infection [5] . However, the magnitude of the temporal change is substantially greater in HIV-positive persons [6] .
The mechanism through which HIV infection may increase HCV RNA levels is unknown. The correlation with CD4 ϩ lymphocyte decline has led to the conjecture that HIV affects HCV RNA levels by immune suppression, a supposition that is indirectly supported by the finding of lower HCV RNA levels in persons with more vigorous CD8 ϩ cytotoxic T cell responses [12] . However, in the present study, even among women with CD4 ϩ lymphocyte counts у500 cells/mL, in whom most adverse effects of T cell deficiency were not clinically evident, there was a strong relationship between HIV and HCV RNA levels. The stronger correlation of HCV RNA level with HIV RNA level could indicate an alternate (or additional) direct viral interaction. However, although there is recent evidence that HCV may replicate in mononuclear cells, the serum HCV RNA level probably reflects intrahepatic replication, whereas serum HIV levels represent replication elsewhere [13] . Unfortunately, data in this cross-sectional analysis are not sufficient to enable us to infer causality.
In this investigation, persons with HCV RNA levels that were not detectable by the quantitative assay were excluded from further analysis. This was necessary, because the factors that affect HCV RNA clearance could differ from those that affect the level of viremia in persistently infected persons, as suggested elsewhere [5, 14] . Indeed, in this analysis, white women and HBV-infected women were more likely to have undetectable HCV RNA, but white women and HBV-infected women with detectable levels did not have lower levels of HCV RNA. Moreover, to carefully differentiate viral clearance from low-level viremia, additional serial HCV RNA testing using more sensitive assays would be needed.
The present study adds to knowledge about HCV RNA levels by including information derived from the largest number of women with or at risk for HIV infection reported to date and from women of different ethnic backgrounds and different geographic areas. However, despite the large number of women examined, only 6% of the person-to-person variability in HCV RNA levels was explained by factors evaluated in this study. This finding is similar to that of another recent large investigation of HCV RNA levels [5] and indicates that the measured level of HCV RNA is chiefly determined by factors that have yet to be identified.
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